capivasertib + paclitaxel

Capivasertib (AZD5363) is a highly potent, selective oral small molecule inhibitor of the serine/threonine kinase AKT (protein kinase B), with activity against all three isoforms—AKT1, AKT2, and AKT3. It blocks the PI3K/AKT signaling pathway that is frequently activated in various cancers including breast cancer. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination of capivasertib and paclitaxel has been investigated in clinical trials for advanced or metastatic breast cancer—including estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC)—to assess whether inhibition of the PI3K/AKT pathway can enhance sensitivity to chemotherapy. Capivasertib may be particularly effective in tumors with PIK3CA mutations or PTEN loss[1][2][5][6].

Other names

capivasertib + paclitaxel